The prize is better outcomes, but the price may be sharing more personal details. Lawyers are working on the new rules ...

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised ...

The Chicago-based Tempus spinout called the financing round a major milestone as it expands its AI-enabled platform.

In the assessment of 12-month price targets, analysts unveil insights for Tempus AI, presenting an average target of $64.09, ...

Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest ...

Boehringer will gain access to the de-identified database of Tempus, which comprises clinical, imaging and molecular data.

"By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our ...

GeneDx is expanding product lines, improving margins, and increasing insurance coverage, with the recent acquisition. Read ...

On Tuesday, the Labor Department reported that the Consumer Price Index for April rose by only 0.2 percent last month, ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

Despite a turbulent 2025, Ark Invest CEO Cathie Wood is currently sitting on a big win with her investment in Tempus AI ...